EEG results revealed a surge in brain entropy within an hour of taking psilocybin. Those with the largest spike in brain entropy reported better wellbeing a month later—indicating that these neural connections may indeed foster long-term mental health benefits.

Key findings:

• A single dose of psilocybin can induce anatomical changes in the brain.
• Changes in brain structure were still apparent a month after taking psilocybin.
• The study involved 28 healthy volunteers who had never taken a psychedelic before.
• Participants took a 25mg dose of psilocybin to elicit a powerful psychedelic experience.
• Those with the largest spike in brain entropy reported improved wellbeing one month later.

This study aligns with Texas’s increasing interest in psychedelic therapy. In recent years, Texas has passed legislation funding psychedelic research, particularly for veterans grappling with PTSD. Furthermore, the FDA is fast-tracking several psychedelic compounds for mental health conditions like treatment-resistant depression and major depressive disorder.

Prof. Robin Carhart-Harris remarked, “It’s remarkable to see potential anatomical brain changes one month after a single dose of any drug.” This underscores the urgency for further exploration into the therapeutic potentials of psychedelics.

Yet, uncertainties linger around safety and efficacy—especially concerning other compounds like ibogaine, which has known risks requiring trained medical oversight. As interest grows, it’s crucial to navigate these complexities carefully.

The stakes are high: over 49,000 Americans died by suicide in 2023 alone. With such alarming figures prompting renewed interest in innovative treatments, research into psychedelics could be pivotal. Logan Davidson noted, “Nothing we’re seeing play out on the national stage would have happened without Texas,” highlighting the state’s role as a catalyst for change in psychedelic policy and research.

The post Psychedelic Drug Study Reveals Lasting Brain Changes appeared first on News Canada.

In April 2021, the FDA lifted the in-person dispensing requirement for mifepristone due to the Covid-19 pandemic. In a surprising turn, this requirement was permanently lifted in 2023. Yet, recent court rulings have thrown this progress into disarray.

The Fifth Circuit Court of Appeals issued a stay that blocks the use of mifepristone, directly impacting its availability. U.S. District Judge Matthew Kacsmaryk suspended the FDA’s approval of mifepristone, leading to confusion and upheaval in medical practices.

As a response, organizations like Planned Parenthood are adapting. Nicole Clegg, President and CEO of Planned Parenthood of Northern New England, remarked on their strategy: “We closely monitored this court case, and we identified a way to keep telehealth medication abortion access intact for our patients.” They plan to switch to misoprostol-only for telehealth patients.

This legal turmoil stems from a lawsuit filed by individual doctors and medical groups opposed to abortion. The FDA and several leading medical groups argue that mifepristone is safe and effective. However, the court’s decisions suggest otherwise.

Danco Laboratories and GenBioPro manufacture mifepristone, which is typically used alongside misoprostol for medication abortions. The combination has been standard practice since mifepristone’s approval back in 2000.

Now, with the legal landscape shifting rapidly—regulatory chaos looms. GenBioPro stated that “the order has unleashed regulatory chaos,” highlighting the immediate impact on healthcare providers.

The next significant legal ruling is expected in early 2024 concerning the case FDA v. Alliance for Hippocratic Medicine. Until then, uncertainty reigns over how these legal battles will shape abortion access moving forward.

The post Mifepristone: Legal Battles Reshape Abortion Access appeared first on News Canada.